Featured Research

from universities, journals, and other organizations

Innovative 'genotype first' approach uncovers protective factor for heart disease

Date:
July 31, 2014
Source:
Broad Institute of MIT and Harvard
Summary:
Extensive sequencing of DNA from thousands of individuals in Finland has unearthed scores of mutations that destroy gene function and are found at unusually high frequencies. Among these are two mutations in a gene called LPA that may reduce a person's risk of heart disease. These findings are an exciting proof-of-concept for a new 'genotype first' approach to identifying rare genetic variants associated with, or protecting from, disease followed by extensive medical review of carriers.

Extensive sequencing of DNA from thousands of individuals in Finland has unearthed scores of mutations that destroy gene function and are found at unusually high frequencies. Among these are two mutations in a gene called LPA that may reduce a person's risk of heart disease. These findings are an exciting proof-of-concept for a new "genotype first" approach to identifying rare genetic variants associated with, or protecting from, disease followed by extensive medical review of carriers. The new study by researchers from the Broad Institute, Massachusetts General Hospital (MGH), the University of Helsinki, and an international team of collaborators appears in a paper published online July 31 in PLOS Genetics.

The researchers studied exomes -- the portions of the genome that correspond to protein-coding genes -- from 3,000 Finns and compared them to those of 3,000 non-Finnish Europeans. They identified 83 gene-deactivating variants that were at least twice as prevalent in Finns and went on to study these variants in over 35,000 Finns. Recent examples in heart disease, HIV, type 2 diabetes and Crohn's disease have demonstrated that such mutations -- known as "loss-of-function" mutations -- in some cases protect from, rather than cause, disease and thereby suggest new paths toward therapeutics.

Geneticists have known that Mendelian, recessive genetic diseases -such as Tay-Sachs or cystic fibrosis that are caused by a single, mutated gene -- are more common in isolated populations because of a phenomenon known as "bottlenecking." When a small population is isolated for tens to hundreds of generations, the population's genetic diversity becomes restricted, and occasional rare genetic variations can by chance become much more common. While this has long been recognized as the source of the unique rare disease patterns seen in isolated populations, this paper demonstrates that the same principles can help researchers identify rare, loss-of-function variants in genome-wide association studies on these isolated populations.

In the current study, researchers chose to study modern Finns -- a population that descended from a well-documented bottleneck that occurred around 4,000 years ago. Comparing Finns with their non-Finnish European counterparts gave the researchers strong, empirical data.

The LPA gene encodes Lipoprotein(a), a type of lipoprotein, first identified in 1963 and a known risk factor for heart disease. The variants described in this paper reduced levels of LPA gene expression causing lower levels of Lipoprotein(a) in the blood. The research team examined Finnish medical records and found that the loss-of-function variants were not associated with other health problems, making blocking LPA expression a potentially exciting therapeutic approach. The availability of centralized medical records available in Finland enabled the researchers to shift the paradigm of medical genetics to a "genotype first" approach.

"This new approach could significantly change how researchers analyze rare variants for complex diseases. It gives us a window into the genetics of complex diseases that we haven't had before," said co-senior author Mark Daly, co-director of the Program in Medical and Population Genetics at the Broad Institute and chief of the Analytic and Translational Genetics Unit for the Center for Human Genetic Research at MGH. "By combining the information from detailed medical records with the information contained in the genomes of a bottlenecked population, we're uncovering rare variants that contribute to complex diseases."

Heart disease is a leading killer globally. The World Health Organization reports that cardiovascular disease was responsible for 30 percent of all global deaths, or 17.3 million people in 2008. Therapeutics able to specifically address this risk by targeting LPA could have a global impact on medical outcomes.

This work highlights the potential for using rare variant analysis in isolated populations to study complex diseases, an approach that had previously been largely limited to Mendelian traits. The approach can now be applied to other complex diseases that have many contributing genetic factors.

"We've illustrated the validity of this approach by identifying rare, loss-of-function variants with promising therapeutic potential for the treatment of heart disease, but this work also represents a reproducible approach that can be used to increase our understanding of other complex diseases as well," said co-senior author Aarno Palotie (Broad Institute, Massachusetts General Hospital, Harvard Medical School, Institute for Molecular Medicine Finland FIMM, University of Helsinki).


Story Source:

The above story is based on materials provided by Broad Institute of MIT and Harvard. The original article was written by Lisa Girard. Note: Materials may be edited for content and length.


Journal Reference:

  1. Elaine T. Lim, Peter Würtz, Aki S. Havulinna, Priit Palta, Taru Tukiainen, Karola Rehnström, Tõnu Esko, Reedik Mägi, Michael Inouye, Tuuli Lappalainen, Yingleong Chan, Rany M. Salem, Monkol Lek, Jason Flannick, Xueling Sim, Alisa Manning, Claes Ladenvall, Suzannah Bumpstead, Eija Hämäläinen, Kristiina Aalto, Mikael Maksimow, Marko Salmi, Stefan Blankenberg, Diego Ardissino, Svati Shah, Benjamin Horne, Ruth McPherson, Gerald K. Hovingh, Muredach P. Reilly, Hugh Watkins, Anuj Goel, Martin Farrall, Domenico Girelli, Alex P. Reiner, Nathan O. Stitziel, Sekar Kathiresan, Stacey Gabriel, Jeffrey C. Barrett, Terho Lehtimäki, Markku Laakso, Leif Groop, Jaakko Kaprio, Markus Perola, Mark I. McCarthy, Michael Boehnke, David M. Altshuler, Cecilia M. Lindgren, Joel N. Hirschhorn, Andres Metspalu, Nelson B. Freimer, Tanja Zeller, Sirpa Jalkanen, Seppo Koskinen, Olli Raitakari, Richard Durbin, Daniel G. MacArthur, Veikko Salomaa, Samuli Ripatti, Mark J. Daly, Aarno Palotie. Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population. PLoS Genetics, 2014; 10 (7): e1004494 DOI: 10.1371/journal.pgen.1004494

Cite This Page:

Broad Institute of MIT and Harvard. "Innovative 'genotype first' approach uncovers protective factor for heart disease." ScienceDaily. ScienceDaily, 31 July 2014. <www.sciencedaily.com/releases/2014/07/140731145833.htm>.
Broad Institute of MIT and Harvard. (2014, July 31). Innovative 'genotype first' approach uncovers protective factor for heart disease. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2014/07/140731145833.htm
Broad Institute of MIT and Harvard. "Innovative 'genotype first' approach uncovers protective factor for heart disease." ScienceDaily. www.sciencedaily.com/releases/2014/07/140731145833.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins